Skip to main content
. 2018 May 24;13(6):884–892. doi: 10.2215/CJN.11871017

Figure 3.

Figure 3.

Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers at each study visit did not differ by race in ACCORD trial participants. Percentage of use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers by month in black (gray bars) and white (black bars) participants.